Form 4: Adaptive Biotechnologies CEO Sells Shares
Insider Transaction (Form 4)
Chad M Robins, CEO and Chairman and a Director of Adaptive Biotechnologies Corp, sold 600,000 shares of common stock on August 17, 2026.
Summary
- Option exercise/conversion: acquired 321,324 Common Stock at $6.55 ($2,104,672) on August 17, 2026; holds 2,501,842 after (Direct).
- Open-market sale: disposed of 318,799 Common Stock at $25.08 ($7,995,479) on August 17, 2026; holds 2,183,043 after (Direct).
- Open-market sale: disposed of 2,525 Common Stock at $25.57 ($64,564) on August 17, 2026; holds 2,180,518 after (Direct).
- Option exercise/conversion: acquired 278,676 Common Stock at $6.55 ($1,825,328) on August 18, 2026; holds 2,459,194 after (Direct).
- Open-market sale: disposed of 278,472 Common Stock at $24.48 ($6,816,995) on August 18, 2026; holds 2,180,722 after (Direct).
- Open-market sale: disposed of 204 Common Stock at $25.14 ($5,129) on August 18, 2026; holds 2,180,518 after (Direct).
- Option exercise/conversion: disposed of 321,324 Stock Option (right to buy) on August 17, 2026; holds 278,676 after (Direct).
- Option exercise/conversion: disposed of 278,676 Stock Option (right to buy) on August 18, 2026 (Direct).
Sentiment
Score: 2
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $14,882,166 of stock on the open market.
Insider Transactions
Chad M Robins — Director, Officer (CEO and Chairman)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Option exercise/conversion | Common Stock | 321,324 | $7 | $2.1M | 2,501,842 |
| 2026-08-17 | Open-market sale | Common Stock | 318,799 | $25 | $8.0M | 2,183,043 |
| 2026-08-17 | Open-market sale | Common Stock | 2,525 | $26 | $64.6K | 2,180,518 |
| 2026-08-18 | Option exercise/conversion | Common Stock | 278,676 | $7 | $1.8M | 2,459,194 |
| 2026-08-18 | Open-market sale | Common Stock | 278,472 | $24 | $6.8M | 2,180,722 |
| 2026-08-18 | Open-market sale | Common Stock | 204 | $25 | $5.1K | 2,180,518 |
| 2026-08-17 | Option exercise/conversion | Stock Option (right to buy) | 321,324 | — | — | 278,676 |
| 2026-08-18 | Option exercise/conversion | Stock Option (right to buy) | 278,676 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Option exercise/conversion (321,324 shares) |
| 2026-08-17 | Open-market sale (318,799 shares) |
| 2026-08-17 | Open-market sale (2,525 shares) |
| 2026-08-18 | Option exercise/conversion (278,676 shares) |
| 2026-08-18 | Open-market sale (278,472 shares) |
| 2026-08-18 | Open-market sale (204 shares) |
| 2026-08-17 | Option exercise/conversion (321,324 shares) |
| 2026-08-18 | Option exercise/conversion (278,676 shares) |
Keywords
insider transaction, Form 4, ADPT, Adaptive Biotechnologies Corp, bearish, Chad M Robins
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.